Phase 2 Trial to Evaluate the Efficacy and Safety of Dovitinib in Patients (Pts) with Gastrointestinal Stromal Tumor (Gist) Refractory and/or Intolerant to Imatinib (Im)

H. Joensuu,J-Y. Blay, A. Comandone,J. Martin Broto, E. Fumagalli, G.E. Grignani,X. Garcia Del Muro,A. Adenis,C. Valverde Morales,A. Lopez Pousa,O. Bouché,B. Bui,S. Bauer,C. Barone,C. Weiss,S. Crippa, M. Camozzi, R. Castellana,A. Le Cesne

Annals of Oncology（2014）

引用 1|浏览24

暂无评分

摘要

Aim: Sunitinib is approved for advanced GIST resistant/refractory to IM; however, disease control rate (DCR) at 12 wk was only ≈ 40%. Thus, novel therapeutic second-line strategies are needed to improve outcomes. Dovitinib inhibits several tyrosine kinases (eg, FGFR, VEGFR, PDGFR&bgr;, KIT). DOVIGIST (NCT01478373) is a multicenter, single-arm study to evaluate the efficacy and safety of second-line dovitinib in GIST.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要